Proteostasis therapeutics, inc. (PTI)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
Assets
Current assets:
Cash and cash equivalents

33,351

25,008

35,304

28,636

31,584

28,810

19,712

19,930

19,457

29,724

18,192

23,923

15,419

18,613

43,828

42,642

49,807

13,844

Short-term investments

23,753

44,459

42,457

59,385

73,747

89,569

26,692

40,890

43,874

44,738

25,034

33,772

54,746

66,897

56,412

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

294

294

294

294

-

-

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

-

-

-

1,079

730

710

668

445

140

136

918

Prepaids and other current assets

2,489

1,404

1,933

3,066

3,134

2,481

1,930

2,138

1,982

1,377

1,838

2,767

3,748

4,059

-

-

-

180

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,388

1,119

824

-

Total current assets

59,593

70,871

79,694

91,087

108,465

120,860

48,334

62,958

65,607

76,133

46,437

61,486

74,623

90,237

103,073

43,901

50,767

14,942

Operating lease, right-of-use asset

12,318

12,631

12,940

13,246

13,549

13,849

14,147

14,772

15,261

472

-

-

-

-

-

-

-

-

Property and equipment, net

350

394

464

513

563

605

648

699

376

424

12,582

522

504

541

342

456

524

566

Deferred offering costs

-

-

-

-

-

-

-

196

160

-

-

-

-

-

-

-

-

2,744

Other assets

-

-

112

75

88

-

6

15

24

33

41

50

59

68

81

102

123

144

Restricted cash

828

828

828

828

828

828

828

828

828

1,656

1,656

-

294

294

294

294

294

294

Total assets

73,089

84,724

94,038

105,749

123,493

136,142

63,963

79,468

82,256

78,718

60,716

62,058

75,480

91,140

103,790

44,753

51,708

18,690

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

1,201

2,283

4,068

3,160

2,004

1,884

2,145

1,865

1,222

2,098

2,535

2,321

1,451

2,021

2,809

3,741

3,207

3,330

Accrued expenses

4,725

6,864

6,377

6,863

6,519

5,661

8,406

6,522

5,222

6,120

5,855

6,145

4,015

4,328

4,182

3,057

1,172

2,248

Deferred revenue

-

-

-

-

-

-

-

-

-

1,108

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

1,754

2,227

2,417

2,204

4,683

4,326

4,028

4,076

Operating lease liabilities

1,179

1,153

1,129

1,104

1,080

1,056

1,033

1,009

1,671

559

-

-

-

-

-

-

-

-

Short-term borrowings

1,099

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

139

191

205

201

196

191

187

182

Other liabilities

-

-

-

-

-

-

-

-

-

-

756

-

-

-

-

-

-

-

Total current liabilities

8,204

10,300

11,574

11,127

9,603

8,601

11,584

9,396

8,115

9,885

11,039

10,884

8,088

8,754

11,870

11,315

8,594

9,836

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

228

752

1,666

2,543

3,292

4,265

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

35

87

139

191

240

287

Preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

110

Derivative liability

3

3

3

3

3

3

3

3

13

25

3

18

37

91

142

91

57

2

Operating lease liabilities, net of current portion

11,742

12,043

12,340

12,634

12,920

13,196

13,469

13,736

13,999

-

-

-

-

-

-

-

-

-

Other liabilities, net of current portion

-

-

-

-

-

-

-

-

-

-

11,355

-

-

-

-

-

-

-

Total liabilities

19,949

22,346

23,917

23,764

22,526

21,800

25,056

23,135

22,127

9,910

22,397

10,902

8,388

9,684

13,817

14,140

12,183

14,500

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

Convertible preferred stock (Series A and B), $0.001 par value; 0 and 110,057,398 shares authorized as of December 31, 2016 and 2015, respectively; 0 and 104,854,769 shares issued and outstanding as of December 31, 2016 and 2015, respectively; aggregate liquidation preference of $0 and $149,392, respectively, as of December 31, 2016 and 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

112,292

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

-

-

0

Common stock, $0.001 par value; 125,000,000 shares authorized; 52,147,656 and 52,116,629 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

52

52

51

51

51

51

37

37

35

35

26

26

26

26

26

20

20

1

Additional paid-in capital

399,583

398,979

394,858

393,872

392,851

391,825

299,512

298,515

286,851

285,583

241,758

240,661

239,650

238,902

237,989

167,855

167,714

12,115

Accumulated other comprehensive income

43

7

16

33

18

1

-7

-12

-28

-2

-7

-27

-38

-22

-9

-

-

-

Accumulated deficit

-346,538

-336,660

-324,804

-311,971

-291,953

-277,535

-260,635

-242,207

-226,729

-216,808

-203,458

-189,504

-172,546

-157,450

-148,033

-137,262

-128,209

-120,218

Total stockholders’ equity

53,140

62,378

70,121

81,985

100,967

114,342

38,907

56,333

60,129

68,808

38,319

51,156

67,092

81,456

89,973

30,613

39,525

-108,102

Total liabilities and stockholders’ equity

73,089

84,724

94,038

105,749

123,493

136,142

63,963

79,468

82,256

78,718

60,716

62,058

75,480

91,140

103,790

44,753

51,708

18,690